Oncoceutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $81.3M

Oncoceutics General Information

Description

Operator of a clinical-stage drug development company intended to offer class compounds that selectively target G protein-coupled receptors for oncology. The company specializes in the research and development of a lead compound that is an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers, enabling the healthcare industry to get access to compounds that control critical signaling pathways in cancer treatments. .

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncoceutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 07-Jan-2021 $81.3M Completed Generating Revenue
6. Grant 08-Jun-2020 Completed Generating Revenue
5. Debt - PPP 03-May-2020 Completed Generating Revenue
4. Grant 27-Jan-2020 Completed Generating Revenue
3. Later Stage VC (Series A) 14-Feb-2018 Completed Generating Revenue
2. Accelerator/Incubator 11-Dec-2014 $2.5M Completed Clinical Trials - Phase 1
1. Seed Round 23-Sep-2014 $2.5M $2.5M Completed Clinical Trials - Phase 1
To view Oncoceutics’s complete valuation and funding history, request access »

Oncoceutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-3
Series A-2
Series A-1 1,137,772 $0.001000 $4.28 $4.28 1x $4.28 8.19%
Seed 2,795,161 $0.001000 $0.94 $0.94 1x $0.94 20.12%
To view Oncoceutics’s complete cap table history, request access »

Oncoceutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage drug development company intended to offer class compounds that selectively target G protei
Drug Discovery
Philadelphia, PA
20 As of 2021

Lexington, MA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncoceutics Competitors (2)

One of Oncoceutics’s 2 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agenus Formerly VC-backed Lexington, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 2 of 2 competitors. Get the full list »

Oncoceutics Patents

Oncoceutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2023139152-A Imipridone for glioma Active 03-Nov-2017
JP-2026094283-A Imipridone for gliomas Pending 03-Nov-2017
AU-2018360752-A1 Imipridones for gliomas Inactive 03-Nov-2017
AU-2024219839-A1 Imipridones for gliomas Active 03-Nov-2017
AU-2024219839-B2 Imipridones for gliomas Active 03-Nov-2017 A61K31/519
To view Oncoceutics’s complete patent history, request access »

Oncoceutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncoceutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brown University Endowment Limited Partner
Calvert Research Venture Capital Minority
Frontida Biopharm Corporation Minority
National Brain Tumor Society Not-For-Profit Venture Capital
Science Center Accelerator/Incubator
You’re viewing 5 of 7 investors. Get the full list »

Oncoceutics FAQs

  • When was Oncoceutics founded?

    Oncoceutics was founded in 2009.

  • Where is Oncoceutics headquartered?

    Oncoceutics is headquartered in Philadelphia, PA.

  • What is the size of Oncoceutics?

    Oncoceutics has 20 total employees.

  • What industry is Oncoceutics in?

    Oncoceutics’s primary industry is Drug Discovery.

  • Is Oncoceutics a private or public company?

    Oncoceutics is a Private company.

  • What is the current valuation of Oncoceutics?

    The current valuation of Oncoceutics is .

  • What is Oncoceutics’s current revenue?

    The current revenue for Oncoceutics is .

  • How much funding has Oncoceutics raised over time?

    Oncoceutics has raised $20.5M.

  • Who are Oncoceutics’s investors?

    Brown University Endowment, Calvert Research, Frontida Biopharm, National Brain Tumor Society, and Science Center are 5 of 7 investors who have invested in Oncoceutics.

  • Who are Oncoceutics’s competitors?

    Agenus and Inovio Pharmaceuticals are competitors of Oncoceutics.

  • When was Oncoceutics acquired?

    Oncoceutics was acquired on 07-Jan-2021.

  • Who acquired Oncoceutics?

    Oncoceutics was acquired by Chimerix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process